Navigation Links
Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
Date:3/20/2008

SUNRISE, Fla., March 20 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) will report financial results for the year ended December 31, 2007 after the close of the market on Thursday, March 27, 2008. The Company has scheduled a conference call for Thursday, March 27, 2008 at 4:30 p.m. Eastern to discuss these results.

Interested parties can access the call by dialing (877) 858-9308 or (706) 643-0580, or can listen via a live Internet web cast, which can be found at http://www.bioheartinc.com. A replay of the call is available via webcast at http://www.bioheartinc.com for 30 days or by playback at (800) 642-1687 or (706) 645-9291 through March 29, 2008. Please use conference id #: 39978839 for the replay.

About Bioheart, Inc.:

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from the patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell II with SDF-1(TM), a therapy utilizing autologous cells genetically modified to express additional growth factors.

MyoCell and MyoCell II with SDF-1 are registered trademarks of Bioheart, Inc.

Contact: William Kline Lytham Partners, LLC

Chief Financial Officer Joe Diaz

Nicholas Burke Joe Dorame

VP - Financial Operations Robert Blum

(954) 835-1500 (602) 889-9700


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
2. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
3. Vion Reports 2007 Fourth Quarter and Year-End Results
4. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
5. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
6. Warner Chilcott Reports the Death of Its Director James Andress
7. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Unigene Restates Policy on Analyst Reports
10. NPS Pharmaceuticals Reports 2007 Financial Results
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in ... molecular test results from tumors with previously documented positive, negative, and equivocal ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a ... their recent FDA Class II 510(k) clearance for their flagship medical device, SimplECG. ... remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies have ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
(Date:11/30/2016)... Fla. , Nov. 30, 2016 Biotest ... products, is pleased to announce the addition of its ... Kearney, Nebraska . The 15,200 square ... on November 29th, 2016 and brings the total number ... Ileana Carlisle , BPC,s Chief Executive Officer ...
Breaking Biology Technology:
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
Breaking Biology News(10 mins):